Mirae Asset Global Investments
TCRT icon

Mirae Asset Global Investments’s Alaunos Therapeutics TCRT Stock Holding History

Mirae Asset Global Investments’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,097
Closed -$401K – 2446
2022
Q1 		$401K Sell
4,097
-729
-15% -$93.6K ﹤0.01% 1488
2021
Q4 		$789K Buy
4,826
+947
+24% +$208K ﹤0.01% 1355
2021
Q3 		$1.06M Buy
3,879
+726
+23% +$222K ﹤0.01% 1278
2021
Q2 		$1.25M Buy
+3,153
New +$1.47M ﹤0.01% 1191
2021
Q1 		– Sell
-1,646
Closed -$622K – 1608
2020
Q4 		$622K Buy
1,646
+435
+36% +$173K ﹤0.01% 1256
2020
Q3 		$458K Buy
1,211
+375
+45% +$166K ﹤0.01% 1211
2020
Q2 		$411K Buy
836
+357
+75% +$159K ﹤0.01% 1208
2020
Q1 		$176K Buy
479
+53
+12% +$27.4K ﹤0.01% 1340
2019
Q4 		$301K Buy
426
+89
+26% +$61.2K ﹤0.01% 1349
2019
Q3 		$217K Buy
337
+249
+283% +$198K ﹤0.01% 1369
2019
Q2 		$77K Buy
+88
New +$60.5K ﹤0.01% 1384

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Mirae Asset Global Investments's TCRT Position: Q2 2022 in Review

Mirae Asset Global Investments sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 4,097 shares — an estimated $401K sold.

Mirae Asset Global Investments first reported a position in TCRT in Q2 2019 and held it in 11 quarters. The position peaked at $1.25M in Q2 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Mirae Asset Global Investments reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Mirae Asset Global Investments sold 4,097 Alaunos Therapeutics shares in Q2 2022, an estimated $401K.
  • Mirae Asset Global Investments first reported a position in Alaunos Therapeutics in Q2 2019 and held it in 11 quarters.
  • Mirae Asset Global Investments's Alaunos Therapeutics position peaked at $1.25M in Q2 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Mirae Asset Global Investments's 13F filing for Q2 2022, filed 26 Jul 2022.